Lavipharm announced consolidated earnings results for the first half of 2015. For the first half, the company reported sales of EUR 13 million, compared with EUR 14.8 million in the first half of 2014. The company recorded an increase in EBITDA, with the total reaching EUR 1.3 million, compared with LBITDA of EUR 7.4 million in the first half of 2014.

The group's net loss was EUR 4.7 million, compared with a net loss of EUR 21.5 million in the equivalent period last year.